<DOC>
	<DOC>NCT00259766</DOC>
	<brief_summary>The purpose of this study is to compare health-related costs and asthma control in ordinary clinical practice during 12 months for Symbicort® given as a low maintenance dose plus as needed compared to a free combination of Pulmicortâ and Oxis® plus Bricanyl® as needed, and Symbicort fixed dosing plus Bricanyl as needed in asthmatic patients not adequately controlled on inhaled glucocorticosteroids alone.</brief_summary>
	<brief_title>SHARE - Symbicort and Health Economics in a Real Life Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Terbutaline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Signed informed consent, asthma, previously treated with glucocorticosteroids and B2agonist History of smoking, pregnancy, any significant disease or disorder which may put the patient at risk because of study participation</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>